Marrow Therapeutics

United States · Biotech · Healthtech

Marrow Therapeutics develops bone marrow-targeted genetic medicines for severe blood disorders.

Product

Marrow aims to treat sickle cell disease, beta thalassemia and other blood disorders by delivering therapeutic payloads directly to bone marrow cells. Its Transferrin Antibody Bioconjugate platform uses engineered antibodies to target the transferrin receptor. Lead candidate MAR-101 is in studies preparing for an investigational clinical-trial application.

Funding history

2 rounds · 2 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$120MOrbiMed — LeadAffinity Advisors — ParticipantColumbia Threadneedle Investments — ParticipantKKR — ParticipantNEXTBio Capital — ParticipantOpaleye — ParticipantRTW Investments — ParticipantScion Life Sciences — ParticipantSpruce Street Capital — ParticipantSurveyor Capital — ParticipantvenBio — Participant
Series A financing disclosure$53MScion Life Sciences — LeadvenBio — Lead
Sourcesmarrowtx.com ↗